CTSA Visiting Scholar – Therapeutic Advances in Hereditary Hemorrhagic Telangiectasia
VirtualJoin Hanny Al-Samkari, MD for a presentation describing the revolutionary potential of anti-angiogenic therapy in hereditary hemorrhagic telangiectasia (HHT) and the evidence to date for systemic bevacizumab as a treatment for bleeding and anemia in HHT.